MiMedx Group, Inc. (NASDAQ:MDXG) Shares Purchased by Massachusetts Financial Services Co. MA

Massachusetts Financial Services Co. MA boosted its position in shares of MiMedx Group, Inc. (NASDAQ:MDXG) by 3.5% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 183,263 shares of the company’s stock after buying an additional 6,143 shares during the period. Massachusetts Financial Services Co. MA’s holdings in MiMedx Group were worth $1,270,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Headlands Technologies LLC acquired a new position in shares of MiMedx Group in the 1st quarter valued at $27,000. Isthmus Partners LLC grew its position in MiMedx Group by 30.4% during the 2nd quarter. Isthmus Partners LLC now owns 393,214 shares of the company’s stock worth $27,000 after purchasing an additional 91,714 shares during the last quarter. Quest Partners LLC acquired a new position in MiMedx Group in the second quarter valued at $81,000. Entropy Technologies LP purchased a new stake in shares of MiMedx Group in the first quarter valued at about $99,000. Finally, Shell Asset Management Co. acquired a new stake in shares of MiMedx Group during the first quarter worth about $113,000. Hedge funds and other institutional investors own 79.15% of the company’s stock.

MiMedx Group Stock Performance

Shares of MDXG stock opened at $6.13 on Monday. The company has a current ratio of 3.85, a quick ratio of 3.22 and a debt-to-equity ratio of 0.11. The stock has a 50 day simple moving average of $6.67 and a 200-day simple moving average of $7.01. The company has a market cap of $904.81 million, a price-to-earnings ratio of 13.93 and a beta of 1.98. MiMedx Group, Inc. has a 12-month low of $5.57 and a 12-month high of $9.27.

MiMedx Group (NASDAQ:MDXG) last released its quarterly earnings data on Wednesday, July 31st. The company reported $0.08 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.08. MiMedx Group had a return on equity of 34.24% and a net margin of 23.63%. The firm had revenue of $87.21 million during the quarter, compared to analysts’ expectations of $88.44 million. On average, equities analysts forecast that MiMedx Group, Inc. will post 0.26 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on MDXG. Cantor Fitzgerald restated an “overweight” rating and issued a $11.00 price target on shares of MiMedx Group in a research report on Thursday, August 1st. StockNews.com raised MiMedx Group from a “buy” rating to a “strong-buy” rating in a report on Wednesday, September 4th. Finally, Craig Hallum lowered their price objective on shares of MiMedx Group from $14.00 to $12.00 and set a “buy” rating on the stock in a research report on Thursday, August 1st. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $12.00.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.